Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 4
1996 5
1997 6
1998 2
1999 4
2000 3
2001 2
2002 3
2003 2
2004 3
2005 4
2006 7
2007 4
2008 2
2009 1
2010 3
2011 2
2012 3
2013 4
2014 5
2015 1
2016 3
2017 5
2018 5
2019 5
2020 2
2021 1
2022 9
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.
Chalmers SA, Ayilam Ramachandran R, Garcia SJ, Der E, Herlitz L, Ampudia J, Chu D, Jordan N, Zhang T, Parodis I, Gunnarsson I, Ding H, Shen N, Petri M, Mok CC, Saxena R, Polu KR, Connelly S, Ng CT, Mohan C, Putterman C. Chalmers SA, et al. J Clin Invest. 2022 Jan 4;132(1):e147334. doi: 10.1172/JCI147334. J Clin Invest. 2022. PMID: 34981775 Free PMC article.
T cells are central to the pathogenesis of lupus nephritis (LN), a common complication of systemic lupus erythematosus (SLE). CD6 and its ligand, activated leukocyte cell adhesion molecule (ALCAM), are involved in T cell act …
T cells are central to the pathogenesis of lupus nephritis (LN), a common complication of systemic lupus erythematosus (SLE). CD6 and …
ALCAM-CD6 in lupus nephritis.
Allison S. Allison S. Nat Rev Nephrol. 2022 Mar;18(3):137. doi: 10.1038/s41581-022-00548-1. Nat Rev Nephrol. 2022. PMID: 35105972 No abstract available.
ALCAM and CD6--multiple sclerosis risk factors.
Wagner M, Bilinska M, Pokryszko-Dragan A, Sobczynski M, Cyrul M, Kusnierczyk P, Jasek M. Wagner M, et al. J Neuroimmunol. 2014 Nov 15;276(1-2):98-103. doi: 10.1016/j.jneuroim.2014.08.621. Epub 2014 Aug 30. J Neuroimmunol. 2014. PMID: 25216742
ALCAM and CD6 may play an important role in the pathogenesis of multiple sclerosis (MS), since they are involved in the transmigration of leukocytes across the blood-brain barrier. In this study, we confirmed our previous findings about the association of the ALC …
ALCAM and CD6 may play an important role in the pathogenesis of multiple sclerosis (MS), since they are involved in the transm …
Mesenchymal Stromal Cells Suppress T-Cell-Mediated Delayed-Type Hypersensitivity via ALCAM-CD6 Interaction.
Cho WJ, Mittal SK, Chauhan SK. Cho WJ, et al. Stem Cells Transl Med. 2023 Apr 17;12(4):221-233. doi: 10.1093/stcltm/szad012. Stem Cells Transl Med. 2023. PMID: 36972356 Free PMC article.
Our controlled coculture assays demonstrated that ALCAM-CD6 pathway is critical for MSCs to exert its suppressive function on early CD4+CD25- T-cell activation. Moreover, neutralizing ALCAM or CD6 results in the abrogation of MSC-mediated suppre …
Our controlled coculture assays demonstrated that ALCAM-CD6 pathway is critical for MSCs to exert its suppressive function on …
ALCAM/CD166: cancer-related issues.
Weidle UH, Eggle D, Klostermann S, Swart GW. Weidle UH, et al. Cancer Genomics Proteomics. 2010 Sep-Oct;7(5):231-43. Cancer Genomics Proteomics. 2010. PMID: 20952758 Review.
Activated leucocyte adhesion molecule (ALCAM) was originally identified as a transmembrane receptor which is involved in T-cell activation and has other still unresolved functions in hematopoiesis, development, inflammation and transendothelial migrati …
Activated leucocyte adhesion molecule (ALCAM) was originally identified as a transmembrane receptor which is involved i …
CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies.
Aragón-Serrano L, Carrillo-Serradell L, Planells-Romeo V, Isamat M, Velasco-de Andrés M, Lozano F. Aragón-Serrano L, et al. Int J Mol Sci. 2023 Dec 15;24(24):17510. doi: 10.3390/ijms242417510. Int J Mol Sci. 2023. PMID: 38139340 Free PMC article. Review.
Cancer management still requires more potent and safer treatments, of which immunomodulatory receptors on the lymphocyte surface have started to show promise in new cancer immunotherapies (e.g., CTLA-4 and PD-1). CD6 is a signal-transducing transmembrane receptor, mainly e …
Cancer management still requires more potent and safer treatments, of which immunomodulatory receptors on the lymphocyte surface have starte …
Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis.
Kenney HM, Rangel-Moreno J, Peng Y, Chen KL, Bruno J, Embong A, Pritchett E, Fox JI, Becerril-Villanueva E, Gamboa-Domínguez A, Quataert S, Muthukrishnan G, Wood RW, Korman BD, Anolik JH, Xing L, Ritchlin CT, Schwarz EM, Wu CL. Kenney HM, et al. Front Immunol. 2023 Aug 25;14:1237498. doi: 10.3389/fimmu.2023.1237498. eCollection 2023. Front Immunol. 2023. PMID: 37691918 Free PMC article.
T-cells were increased 8-fold in Advanced PLNs, and bioinformatic pathway assessment identified the interaction between ALCAM(+) macrophages and CD6(+) T-cells as a plausible co-stimulatory mechanism to promote IgG2b class-switching. DISCUSSION: Collectively, these …
T-cells were increased 8-fold in Advanced PLNs, and bioinformatic pathway assessment identified the interaction between ALCAM(+) macr …
Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation.
Rambaldi B, Kim HT, Arihara Y, Asano T, Reynolds C, Manter M, Halpern M, Weber A, Koreth J, Cutler C, Gooptu M, Nikiforow S, Ho VT, Antin JH, Romee R, Ampudia J, Ng C, Connelly S, Soiffer RJ, Ritz J. Rambaldi B, et al. Haematologica. 2022 Nov 1;107(11):2617-2629. doi: 10.3324/haematol.2021.280444. Haematologica. 2022. PMID: 35484649 Free PMC article. Clinical Trial.
CD6 is a co-stimulatory receptor expressed on T cells that binds activated leukocyte cell adhesion molecule (ALCAM), expressed on antigen presenting cells, epithelial and endothelial tissues. The CD6-ALCAM pathway pla …
CD6 is a co-stimulatory receptor expressed on T cells that binds activated leukocyte cell adhesion mol …
Polymorphisms in the CD6-ALCAM axis may modulate psoriasis risk and outcomes.
Wagner M, Sobczyński M, Wiśniewski A, Matusiak Ł, Kuśnierczyk P, Jasek M. Wagner M, et al. Hum Immunol. 2024 May;85(3):110797. doi: 10.1016/j.humimm.2024.110797. Epub 2024 Apr 5. Hum Immunol. 2024. PMID: 38580538
The fact that CD6, along with its ligand - ALCAM, plays a role in regulating T cell activation makes the genes encoding these molecules promising candidates for research in T cell-mediated diseases such as psoriasis vulgaris (PsV). ...Collectively, our …
The fact that CD6, along with its ligand - ALCAM, plays a role in regulating T cell activation makes the genes encoding …
Dynamic coupling of ALCAM to the actin cortex strengthens cell adhesion to CD6.
Te Riet J, Helenius J, Strohmeyer N, Cambi A, Figdor CG, Müller DJ. Te Riet J, et al. J Cell Sci. 2014 Apr 1;127(Pt 7):1595-606. doi: 10.1242/jcs.141077. Epub 2014 Feb 4. J Cell Sci. 2014. PMID: 24496453
At the immunological synapse, the activated leukocyte cell adhesion molecule (ALCAM) on a dendritic cell (DC) and CD6 molecules on a T cell contribute to sustained DC-T-cell contacts. However, little is known a …
At the immunological synapse, the activated leukocyte cell adhesion molecule (ALCAM) on a dendriti …
105 results